Ilumink, a fresh spin-out of the University of Cambridge, is building links with industry and raising seed financing to commercialise technology which aims to disrupt the counterfeit drug black market.

The company is developing liquid crystal lasers, spun out from the university’s engineering department and funded by the Royal Academy of Engineering, which can be printed onto labels and make it easier to detect counterfeit drugs. The laser also has the advantage of being hard to replicate, but cheap to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?